Crossject Appoints Tony Tipton as U.S. COO for ZEPIZURE Launch
Crossject Appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment
Press Release
Crossject Appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment
Experienced executive to lead preparations for U.S. commercialization of ZEPIZURE.
This move reinforces and de-risks pre-commercial activities ahead of submitting the marketing authorization application for the ZEPIZURE epilepsy rescue treatment in the U.S.
Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations through its award-winning needle-free auto-injector ZENEO®, announces the appointment of Tony Tipton as U.S. Chief Operating Officer.
Mr. Tipton brings over 25 years of experience across essential areas of the commercial pharmaceuticals business, including corporate leadership, business development, market access, sales leadership, and marketing operations. He previously held the position of Chief Operating & Commercial Officer at Xequel Bio, where he developed and implemented a commercialization strategy and managed pre-commercial activities for BARDA/NIH funded assets, along with overseeing commercial assets through acquisition. His appointment is expected to strengthen Crossject’s pre-commercial activities in the U.S. as the company readies its marketing authorization application submission for ZEPIZURE.
Before joining Crossject, Mr. Tipton held several significant commercial roles in major international specialty pharmaceutical companies, including Interim Chief Commercial Officer and Vice President of Market Access & Trade Channels at Santen Pharmaceuticals, following its acquisition of Eyevance Pharmaceuticals. Here, he effectively led U.S. commercial functions that resulted in over $70 million in gross revenue. His extensive background includes a Director’s position for Health Systems Accounts at Sunovion Pharmaceuticals, where he successfully launched the epilepsy drug Aptiom, among other sales and marketing roles at Galderma Laboratories.
“Tony brings to Crossject a proven track record of excellence and highly relevant experience across all facets of pre-commercial, sales, and marketing in the specialty pharmaceutical industry and, specifically, for emergency medicines comparable to ZEPIZURE. His leadership and knowledge are well-suited to guide us toward our commercialization goals in the U.S., which is our key market. We look forward to the dynamic contributions he will bring to our team,” said Patrick Alexandre, CEO of Crossject.
“My senior leadership roles in preparing companies for commercialization have provided me with relevant experience and valuable networks. Joining Crossject at this pivotal moment is a responsibility I am eager to embrace as we seek to bring lifesaving rescue medicines like ZEPIZURE to market. The ZENEO technology platform and Crossject’s promising pipeline present numerous expansion opportunities. I look forward to leveraging my commercial strategy experience and collaborating with the talented team at Crossject as we aim to launch the company’s first rescue therapy,” commented Tony Tipton, COO of Crossject U.S.
About Crossject
Crossject SA (Euronext: ALCJ) is an emerging specialty pharmaceutical company focused on developing medicines for emergency scenarios using its award-winning needle-free auto-injector ZENEO® platform. Crossject is in the advanced stages of regulatory development for ZEPIZURE, an epilepsy rescue therapy, backed by a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The versatile ZENEO® platform is designed to allow patients or untrained caregivers to swiftly and easily administer a variety of emergency medications intramuscularly, even through clothing. The company is also developing other products targeting allergic reactions, adrenal insufficiency, and other emergency conditions.
Contact Information
Investors
Natasha Drapeau
Cohesion Bureau
+41 76 823 75 27
natasha.drapeau@cohesionbureau.com
Media
Sophie Baumont
Cohesion Bureau
+33 6 27 74 74 49
sophie.baumont@cohesionbureau.com
Frequently Asked Questions
1. Who has been appointed as the U.S. Chief Operating Officer for Crossject?
Tony Tipton has been appointed as the U.S. Chief Operating Officer for Crossject.
2. What is ZEPIZURE?
ZEPIZURE is an epilepsy rescue treatment developed by Crossject, utilizing their advanced needle-free auto-injector technology.
3. What experience does Tony Tipton bring to Crossject?
Tony Tipton has over 25 years of experience in the pharmaceutical industry, specifically in areas such as corporate leadership, business development, and market access.
4. How does Crossject's ZENEO® platform work?
The ZENEO® platform allows emergency medications to be administered intramuscularly by patients or caregivers easily and rapidly, even through clothing.
5. What other therapeutic areas is Crossject exploring?
Crossject is also developing treatments for allergic shocks, adrenal insufficiencies, and other emergency indications.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Kelun-Biotech Showcases Promising TROP2-ADC Research Insights
- The Future of Hydrogen Power: Is Plug Power Ready for Growth?
- Huawei's Vision for 6G: AI's Role in Network Evolution
- China's Global Initiatives Encourage Global Cooperation and Development
- Shigeru Ishiba Advocates for Accommodative Monetary Policy in Japan
- U.S. Markets Rejoice as Dow Jones Hits Historic Highs
- Duke Energy Makes Significant Progress in Power Restoration Efforts
- UBS Chair Raises Concerns Over Potential Capital Requirement Increases
- Julian Assange's Historic Testimony at the Council of Europe
- Debra Tice Advocates for Hostage Rights at NYC Forum
Recent Articles
- Share Purchase Update for Cargotec Corporation in August 2024
- Technip Energies Share Buyback Report: August 2024 Analysis
- ProPhase Labs Set to Participate in Virtual Investor Summit
- Emerita Resources Secures $6 Million in First Credit Tranche
- IZEA Flex Recognized as Top Influencer Marketing Platform 2024
- AYR Cannabis Expands Retail Presence with New Manchester Store
- Davidson Kempner Capital Management Updates on International Paper
- Davidson Kempner Capital Management LP's Public Disclosure Report
- Resolutions From Vilniaus Baldai AB Shareholders Meeting
- MJ Sully Elevated to Senior Managing Director at Peapack Private
- OSB Group PLC's Recent Shareholding Update and Company Overview
- Anthony Germinaro Joins PetVivo Holdings as Business Manager
- SKYX Partners with EGLO for Lighting Innovations Worldwide
- Ainos Introduces AI Nose Technology Enhancing Factory Safety
- Riksbank Certificates Buyback Overview and Details
- Middlefield Canadian Income PCC Reports Estimated NAV Details
- Peoples Bancorp Announces Regular Cash Dividend Payment
- Mullen's Class 3 EV Truck Order for Sustainability Initiatives
- AlphaVest Acquisition Corp Enters Merger Agreement with AMC Corp
- Manager's Transactions Report for Schouw & Co. Revealed
- Spirit Blockchain Capital Teams Up with SlamNet for SLAM Token
- Board Transactions Reporting and Company Overview of Svitzer
- Telos Corporation Expands TSA PreCheck Enrollment Locations
- United Health Products Update on FDA Approval Process
- Accelerating Deployment of Battery Storage Solutions Across Asia
- Pandora's Share Buyback Program: Latest Transactions and Impact
- JSC “Latvijas G?ze” to Leave Baltic Secondary List Soon
- Sonnet BioTherapeutics Initiates Phase 1/2a Study for SON-1210
- Mudra Band Offers Gesture Control for All Apple Devices
- Novo Nordisk A/S Announces Major Share Buyback Program
- 4Point Wealth Management Partners with LPL Strategic Wealth Services
- Mandatory Notification of Insider Trade Submission
- SEALSQ Launches QS7001: A Breakthrough in IoT Cybersecurity
- First Merchants Corporation Declares Cash Dividend Announcement
- Phathom Pharmaceuticals Pricing of $130M Offering of Shares
- Spectral AI's Upcoming Presentation on Burn Wound Assessment
- Alliance Trust PLC - Latest Net Asset Value Update
- American Rare Earths Updates on Cowboy State Mine Drilling Progress
- Azrieli Group Sees Strong Q2/2024 Performance with Growth
- Auction Results for RIKV 24 1120 and RIKV 25 0219 Treasury Bills
- MariMed Expands with New Dispensary Opening in Maryland
- Prairie Operating Co. Secures $24 Million from Warrant Exercise
- Intermap Advances GPS Solutions with New U.S. Air Force Contract
- Gray Media Unveils Comprehensive Coverage Plans for 2024 DNC
- Getty Images to Showcase Stunning Imagery at Paris Paralympics
- D-BOX Enhances Motorsport Simulation with FIA Licensing Renewal
- AIP Realty Trust Completes Second Tranche of Financing Round
- BridgeBio Introduces MyAchonJourney for Families Facing Challenges
- SL Green Realty Declares Monthly Dividend for Stockholders
- PDD Holdings Schedules Q2 2024 Financial Results Release